TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Recent Events
TNI BioTech, Inc., Bethesda, MD – (OTC PINK: TNIB), a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using its patented immunotherapy, issued a letter to its shareholders from CEO Noreen Griffin and the company's board of directors. The letter follows:
The board of directors of TNI BioTech, Inc. is very pleased to provide an update on the progress made over the last year. This update gives the company opportunity to provide detailed reviews of several key achievements, as well as share a brief outline of the steps being taken to maximize shareholder value over the coming months.
The company, as of May 15, 2013, filed its first Q1 2013 financials with the Securities and Exchange Commission and OTC markets. This milestone, in conjunction with the filing of a Form 10, allows the company to become fully reporting. While waiting for approval of its Form 10, the company will file the required documents to trade on the QX OTC market, providing improved transparency to the investment community.
TNI BioTech, Inc. Appoints Industry Veteran, Dr. Joseph Fortunak, as a Strategic Consultant
Bethesda MD – TNI BioTech, Inc. (OTC PINK: TNIB) announced today the appointment of industry veteran, Dr. Joseph M. Fortunak, as a strategic consultant to the company. Dr. Fortunak is the former director and head of Global Chemical Development at Abbott Laboratories Corporation, where he managed more than 350 scientists and technical experts.
Dr. Fortunak spent 10 years at SmithKline Beecham (now part of GlaxoSmithKline) working in process chemistry and drug development. Dr. Fortunak worked for 8 years at DuPont Pharmaceuticals, rising to the level of executive director of chemical development. From 2000-2004, Dr. Fortunak then served as the head of Global Chemical Development for Abbott Labs. While in the industry, Dr. Fortunak made significant contributions to 15 new chemical entities for the treatment of HIV/AIDS, malaria, cancer, and various cardiovascular and central nervous system (CNS) indications. He also contributed to roughly 20 new generic drug launches.
TNI BioTech Names Terry Lierman of Summit Global Ventures as a Strategic Advisor
Bethesda MD – April 25, 2013 – TNI BioTech, Inc. (PINK -TNIB) is pleased to announce that they have named Terry Lierman from the Summit Global Ventures as a strategic advisor to the company. In this capacity, Mr. Lierman will provide strategic and tactical direction to improve operational productivity for the company's growth plans.
"Terry Lierman is renowned on capitol hill for both his political skills and his passionate support of improved healthcare and funding for medical research. He has proven over the last four decades that he has the ability to combine his entrepreneurial and political talents." said Noreen Griffin, chief executive officer and director of TNI Biotech, Inc. "His executive experience in the field of healthcare, especially as it applies to cancer and HIV/AIDS, will be invaluable over the coming year." Terry Lierman has served in leadership positions on the staff of the U.S. Senate, and is the founder of a number of companies and non-profit organizations that advance healthcare advocacy.